Chemours (CC) has drawn fresh attention after signing a joint development agreement with 2CRSi to advance two phase immersion cooling for data centers and AI infrastructure, alongside a wave of updated analyst views.
See our latest analysis for Chemours.
The latest 1 day share price return of negative 3.9% and 7 day slide of 15.1% sit against a 90 day share price gain of 35.4% and 1 year total shareholder return of 18.9%. This suggests momentum has cooled recently after a stronger run.
If Chemours’ AI data center push has caught your eye, it could be a good moment to see what else is shaping this theme through our screener of 33 AI infrastructure stocks.
With Chemours trading at $17.32, carrying an estimated intrinsic value gap of around 64% and sitting close to the average analyst target of about $18.89, is there still a mispricing here, or is the market already factoring in future growth?
Most Popular Narrative: 6% Overvalued
At $17.32, Chemours sits modestly above the most followed fair value estimate of about $16.33, which is built on detailed long term earnings and margin assumptions.
Secular demand growth for advanced materials tied to electrification, renewables, data centers, and energy storage is generating incremental sales in higher value applications for APM; ongoing portfolio optimization and pricing improvements in these segments are structurally improving net margins and improving earnings quality.
Curious what kind of revenue profile and margin reset sits behind that fair value, and how it connects to future earnings power and valuation multiples? The full narrative lays out the numbers, the timeframes, and the assumptions driving that $16 range.
Result: Fair Value of $16.33 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the picture could change quickly if PFAS litigation leads to heavier cash costs than expected or if TiO2 pricing pressure keeps margins below those fair value assumptions.
Find out about the key risks to this Chemours narrative.
Another Angle On Value
While the most followed narrative tags Chemours as around 6% overvalued at $17.32, our DCF model points in the opposite direction, with a future cash flow value of $48.64 and a 64.4% discount. That is a big gap. Which story do you think is closer to reality?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
The article so far highlights mixed signals, so if you feel torn, that is normal. However, act quickly and weigh 3 key rewards and 2 important warning signs to shape your own view.
Looking for more investment ideas?
If you are weighing Chemours and still have cash to deploy, do not stop here. Broaden your watchlist with a few focused screens that surface very different types of opportunities.
- Target potential mispricings by reviewing companies our screener highlights as 54 high quality undervalued stocks with solid fundamentals already in place.
- Strengthen your income stream by scanning for reliable payers in our list of 15 dividend fortresses that may suit a more cash focused portfolio.
- Dial down portfolio risk by checking out the 80 resilient stocks with low risk scores that our models flag with more resilient profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com